

BEST OF ASTRO 2020



22. a 23. 3. 2021 vždy od 14.00 – 16.00

Stream z Fakultní nemocnice Olomouc

POŘADATEL:

Onkologická klinika FN Olomouc

ODBORNÝ GARANT:

prof. MUDr. Bohuslav Melichar, Ph.D., Přednosta Onkologické kliniky FN Olomouc
doc. MUDr. Martin Doležel, Ph.D., Onkologická klinika FN Olomouc
Ing. Čeněk Merta, Ph. D., MBA, MPA, Obchodní náměstek FN Olomouc

SBORNÍK ABSTRAKT

22. 3. 2021 14:00 – 14:30

Track 1 - **Gastrointestinal** (Renata Soumarová)

Abstract 1: (95) Nonoperative management versus surgery in patients with complete endoscopic response to neoadjuvant therapy for rectal cancer

Abstract 2: (96) Complete clinical response after short-course radiation and sequential multi-agent chemotherapy for nonoperative treatment of rectal adenocarcinoma

Abstract 3: (174) A Genotype Signature for Predicting Pathologic Complete Response in Locally Advanced Rectal Cancer

Abstract 4: (175) Serial Circulating Tumor DNA for Evaluating Early Response During Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: Preliminary Analysis of A Prospective Biomarker Study

Abstract 5: (1070) Phase I Study of Stereotactic Body Radiotherapy followed by Ipilimumab with Nivolumab vs. Nivolumab alone in Unresectable Hepatocellular Carcinoma

Abstract 6: (1072) Relationship of Dose to Vascular Target Volumes and Local Failure in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemoradiation

Abstract 7: (3321) Stereotactic Body Radiotherapy vs Transarterial Chemoembolisation in locally advanced hepatocellular carcinoma (HERACLES: HEpatocellular carcinoma stereotactic RAdiotherapy CLinical Efficacy Study)

22. 3. 2021 14:30 – 15:00

Track 2 - **Genitourinary** (Karel Odrážka)

Abstract 8: (4) Salvage Low Dose Rate Prostate Brachytherapy: Clinical Outcomes of a Phase II Trial for Local Recurrence after External Beam Radiotherapy (NRG/RTOG -0526)

Abstract 9: (32) Short-Term Adjuvant versus Neoadjuvant Hormone Therapy in Localized Prostate Cancer: A Pooled Individual Patient Analysis of Two Randomized Phase 3 Trials

Abstract 10: (35) Relugolix, A Novel Oral GnRH Receptor Antagonist, versus Leuprolide Depot for Prostate Cancer: The HERO Phase 3 Trial

Abstract 11: (54) Stereotactic Radiotherapy for Oligoprogression in Metastatic Kidney Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Prospective Phase II Multi-Centre Study

Abstract 12: (55) Bladder Preservation with Twice-Daily Radiation plus 5-Fluorouracil/ Cisplatin or Daily Radiation plus Gemcitabine for MIBC – Updated Results of NRG/RTOG 0712: A Randomized Phase 2 Trial

Abstract 13: (126) Five-Year Toxicity after EBRT For Localized Prostate Cancer with or Without a Simultaneously Integrated Focal Boost up to 95Gy: Results of a Randomized Controlled Trial

Abstract 14: (127) An Updated Analysis of Survival Endpoints for ASCENDE-RT, a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer

Abstract 15: (128) Ultra-Hypofractionated versus Conventionally Fractionated Radiation Therapy Boost for Patients with High-Risk, Localized Prostate Cancer: A 5-Year Results from Randomized HYPO-PROST Trial

Abstract 16: (LBA1) Initial Report of a Randomized Trial Comparing Conventional- vs Conventional plus Fluciclovine (18F) PET/CT Imaging-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer

22. 3. 2021 15:00 – 15:30

Track 3 - Head and Neck (Milan Vošmik)

Abstract 17: (178) Risk and Predictors of Late Lower Cranial Neuropathy in Long-term Oropharyngeal Cancer Survivors treated with definitive radiotherapy: A Retrospective Cohort Study among 1,988 Survivors

Abstract 18: (179) Development of Advanced Preselection Tools to Reduce Unnecessary Plan Comparisons in Model-Based Selection of Head and Neck Cancer Patients for Proton Therapy

Abstract 19: (181) Defining Radiotherapy (RT) Coverage for Non-Melanoma Skin Cancer (NMSC) Using Mohs Micrographic Surgery (MMS) Margins

Abstract 20: (222) Nivolumab and ipilimumab combined with definitive radiation therapy in locally advanced squamous cell carcinoma of the head and neck: in-field toxicity analysis of a phase I clinical trials

Abstract 21: (224) Results of a randomized, open label, multicenter trial assessing the safety, dose and schedule of RRx-001(R001) in reducing severe oral mucositis (SOM) in patients receiving chemoradiation (CRT) for oral cavity/oropharynx squamous cell carcinoma (OSCC)

22. 3. 2021 15:30 – 16:00

Track 4 - Breast (Jiří Petera)

Abstract 22: (19) First 2-Year Results of the Multicenter, Randomized IMRT-MC2 Trial (MINT): Intensity-Modulated Radiotherapy with Simultaneous Integrated Boost Versus 3-D-Conformal Radiotherapy with Consecutive Boost for Breast Cancer Patients

Abstract 23: (20) Reconstruction Outcomes in a Multi-Institution Prospective Phase II Hypofractionated Post-Mastectomy Radiation Therapy trial

Abstract 24: (21) Development and Internal Validation of an NTCP-Model for Acute Coronary Events after Breast Cancer Radiotherapy: First Results of the Medirad Brace Study

Abstract 25: (22) A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Epigallocatechin-Gallate in the Prevention of Radiation-Induced Dermatitis

Abstract 26: (24) Patient reported experience with treatment modalities and safety of adjuvant breast radiotherapy- First results of the randomized HYPOSIB – study

Abstract 27: (25) Defining the Optimal Dose for 3D-Conformal Accelerated Partial Breast Irradiation (APBI): 10-years Follow Up of a Dose-Escalation Trial

Abstract 28: (49) Heterogeneity in Outcomes Among Women with Clinically Node-Positive Breast Cancer and Axillary Pathologic Complete Response: An Analysis of NSABP B18, B27, B40, and B41

Abstract 29: (52) De-intensifying Radiation Therapy in HER-2 Positive Breast Cancer: To Boost or not to Boost?

23. 3. 2021 14:00 – 14:30

Track 5 - Gynecological (Martin Doležel)

Abstract 30: (2) Phase III randomized trial of postoperative adjuvant conventional radiation (3DCRT) versus image guided intensity modulated radiotherapy (IG-IMRT) in cervical cancer (PARCER): Final Analysis

Abstract 31: (105) Is the Risk of Substantial LVSI in Stage I Endometrial Cancer Similar to PORTEC in the North American Population? - A Single Institution Study

Abstract 32: (106) Utilizing Immune Profiles to Predict Pelvic Failure in Endometrial Cancer

Abstract 33: (233) Elective inguinal node irradiation is not necessary in cervical cancer invading lower third of vagina

Abstract 34: (234) Hyperthermia Combined with Concurrent Radiochemotherapy for 373 Patients with Cervical Cancer Stage IB-IV

Abstract 35: (238) Assessment of Impact of Bone Marrow Sparing for Haematological and Gastrointestinal Toxicities in Cervical Cancer with External Beam Radiation Therapy

Abstract 36: (3024) Prognostic Significance of Negative Conversion of High-Risk Human Papillomavirus DNA after Treatment in Cervical Cancer Patients

23. 3. 2021 14:30 – 15:00

Track 6 - Lung (Jakub Cvek)

Abstract 37: (3) RTOG0617 to externally validate blood cell ERCC1/2 genotypic signature as a radiosensitivity biomarker for both tumor and normal tissue for individualized dose prescription

Abstract 38: (5) Stereotactic Ablative Fractionated Radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the Lung: A Randomised Phase II Trial

Abstract 39: (147) Safety and Efficacy of a Randomized Phase I Trial to Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients with Stage IV Non-Small Cell Lung Cancer (COSINR Study)

Abstract 40: (217) Randomized phase II trial of metformin in combination with chemoradiotherapy (CRT) in locally advanced Non-Small Cell Lung Cancer (LA-NSCLC); the OCOG-ALMERA trial (NCT02115464).

Abstract 41: (219) Individualized Adaptive Radiotherapy versus Standard Radiotherapy with Chemotherapy for Patients with Locally Advanced Non-small Cell Lung Cancer: A Multicenter Randomized Phase III Clinical Trial CRTOG1601

Abstract 42: (220) A Phase III Randomized Trial of Palliative Radiation for Advanced Central Lung Tumours with Intentional Avoidance of the Esophagus (PROACTIVE)

Abstract 43: (1044) Assessment of Coronary Artery Calcification Burden as a Risk Factor for Cardiac Toxicity in Patients Treated on Radiation Dose-escalation Trials for Stage III Non-small-cell Lung Cancer

Abstract 44: (1045) Statin Use and Major Adverse Cardiac Events among High Cardiac Risk Patients with Lung Cancer Receiving Radiotherapy

Abstract 45: (LBA3) Patterns of Disease Progression after Carboplatin/Etoposide + Atezolizumab in Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)

Abstract 46: (LBA8) Immunomodulatory Low-Dose Whole-Lung Radiation for Patients with COVID-19-Related Pneumonia

23. 3. 2021 15:00 – 15:30

Track 7 - **Central Nervous System** (Tomáš Kazda)

Abstract 47: (39) Impact of Lymphopenia on Survival for Elderly Patients with Glioblastoma: A Secondary Analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) Randomized Clinical Trial

Abstract 48: (40) A phase 2 study of Neo-adjuvant Metformin and Temozolomide followed by Hypofractionated Accelerated RadioTherapy (HART) with concomitant and adjuvant Metformin and Temozolomide (TMZ) in patients with Glioblastoma

Abstract 49: (41) Stereotactic radiosurgery versus whole-brain radiation therapy for patients with 4-15 brain metastases: A phase III randomized controlled trial

Abstract 50: (42) Radiotherapy (RT) dose-intensification (DI) using intensity-modulated RT (IMRT) versus standard-dose (SD) RT with temozolomide (TMZ) in newly diagnosed glioblastoma (GBM): Preliminary results of NRG Oncology BN001

Abstract 51: (1124) Clinical Value and Optimal Timing of Cranial Local Therapy among EGFR-Mutant Non-small-cell Lung Cancer with Brain Metastases in the Era of Osimertinib

Abstract 52: (1155) Timing of Adjuvant Radiotherapy in Atypical Meningiomas

Abstract 53: (1156) Prospective Evaluation of Microscopic Extension using Macropathology in Glioma Patients: Determination of Optimal Clinical Target Volume Margins for Radiotherapy

Abstract 54: (1159) Biomarkers of Post-radiation Cerebellar Injury Are Associated with Neurocognitive Decline in Primary Brain Tumor Patients

23. 3. 2021 15:30 – 16:00

Track 8 - **Best of the Rest** (Martin Doležel)

PROGRAM

22. 3. 2021

14:00 – 14:30

Track 1 - Gastrointestinal (Renata Soumarová)

14:30 – 15:00

Track 2 - Genitourinary (Karel Odrážka)

15:00 – 15:30

Track 3 - Head and Neck (Milan Vošmik)

15:30 – 16:00

Track 4 - Breast (Jiří Petera)

23. 3. 2021

14:00 – 14:30

Track 5 - Gynecological (Martin Doležel)

14:30 – 15:00

Track 6 - Lung (Jakub Cvek)

15:00 – 15:30

Track 7 - Central Nervous System (Tomáš Kazda)

15:30 – 16:00

Track 8 - Best of the Rest (Martin Doležel)

Další informace najdete na:

<https://onkologie.fnol.cz/best-of-astro>



GENERÁLNÍ PARTNER



HLAVNÍ PARTNER



PARTNEŘI

